Optimization of the Management Strategy for Women with Precancerous Changes in the Cervix, Taking into Account New Clinical and Morphological Aspects of Pathology

Abstract

The presented work is devoted to optimizing the management strategy for women with precancerous changes in the cervix, taking into account modern clinical and morphological aspects of pathology. Precancerous changes in the cervix, such as dysplasia and carcinoma in situ, are an important medical problem that requires a comprehensive approach and continuous improvement of clinical methods.

Modern approaches to diagnosis and treatment include the use of colposcopy with biopsy, molecular genetic markers, as well as the latest methods of therapeutic interventions. However, the effectiveness of these measures and their impact on the quality of life of patients require further research and optimization of clinical recommendations.

The aim of this study is to determine the optimal management strategy for patients with precancerous changes in the cervix based on current clinical and morphological data. To achieve this goal, an extensive analysis of the current literature, registry data, and clinical trial results was performed.

Materials and methods included a systematic review of scientific publications, analysis of retrospective data, and results of multicenter studies. Special attention was paid to the morphological aspects of pathology and their influence on the choice of optimal therapy.

The results of the study showed that an individual approach to the management of patients with precancerous conditions of the cervix, based on current clinical data and morphological characteristics of the tumor, contributes to the improvement of clinical and functional outcomes. The effectiveness of this approach is confirmed by improving treatment outcomes and reducing the risk of pathology progression.

The conclusion emphasizes the importance of a personalized approach in the management of patients with precancerous cervical changes, which can significantly improve the prognosis of the disease and the quality of life of patients. Further development of clinical guidelines and introduction of new diagnostic and treatment technologies are necessary to improve current practices and achieve better results in the field of oncogynecology.